VAERS reports by lot

Moderna COVID-19 lot 057M21A: VAERS reports

450 VAERS reports list lot 057M21A as a Moderna COVID-19 vaccine, received between 2022-01-21 and 2024-03-02. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
450
Reports
15%
Marked serious
7
With a death outcome
20
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
General / Systemic (non-local)41425%
Respiratory25015%
Cardiac / Cardiovascular23914%
Gastrointestinal19212%
Neurological17411%
Injection-site / Local reaction1268%
Musculoskeletal755%
Dermatological (non-injection-site)553%
Allergic / Anaphylactic523%
Thrombotic / Hematological362%
Psychiatric / Neuropsychiatric181%
Autoimmune / Immune-mediated141%
Reproductive / Menstrual40%

Where reports came from

U.S. state of the reporter, where given (top 12).

Michigan40
Maine36
South Carolina32
Illinois28
California26
Texas25
Ohio24
Massachusetts17
New York17
Colorado17
Florida16
New Jersey14

Reports by month received

2022-011
2022-0427
2022-05115
2022-0676
2022-0768
2022-0843
2022-0940
2022-1019
2022-118
2022-1210
2023-018
2023-028
2023-032
2023-046
2023-0513
2023-062
2023-121
2024-011
2024-021
2024-031

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.